// App-Quantinova.ai

: Inferior Outcomes for Multiple Myeloma (MM) Patients (pts) Harbouring t(11;14) and the Promise of Venetoclax, Real-World Australian Retrospective

Researchers

Presenter

  • Kenneth JC Lim

Principal Investigators

  • Dipti Talaulikar

  • Joanne L C Tan

  • Joanna Loh

  • Pratheepan Puvanakumar

  • James Anton Kuzich

  • Michelle Ho

  • Matthew Murphy

  • Nicole Zeglinas

  • Sue Morgan

  • Michael S.Y. Low

  • David Routledge

  • Andrew B M Lim

  • Simon D. Gibbs

  • Slavisa Ninkovic

Medical Centers

  • Department of Haematology, St. Vincent's Hospital Melbourne, Melbourne, Australia

  • Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

  • Department of Haematology, Monash Health, Melbourne, Australia

  • Department of Haematology, The Alfred Hospital, Melbourne, Australia

  • Department of Haematology, The Canberra Hospital, Canberra, Australia

  • Monash University, Clayton, AUS

  • Eastern Health, Melbourne, Australia

  • The Canberra Hospital, Canberra, Australia

  • Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, AUS

  • Victorian Cancer Cytogenetics Service, St. Vincent's Hospital Melbourne, Melbourne, Australia

  • School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia

  • Faculty of Medicine, University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, Australia

  • Medical School, The Australian National University, Canberra, Australia

Locations

  • Australia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved